A conceptual framework and ethics analysis for prevention trials of alzheimer disease

Progress in Neurobiology

Volumn 110, Issue , 2013, Pages 114-123

  Peters, Kevin R ^a   Lynn Beattie, B ^b   Feldman, Howard H ^b   Illes, Judy ^b  

^a TRENT UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer Disease; Biomarkers; Ethics; Prevention; Treatment

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GAMMA SECRETASE; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; TARENFLURBIL;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; BRAIN ATROPHY; CEREBROSPINAL FLUID; CONCEPTUAL FRAMEWORK; DECISION TREE; DEMENTIA; DIETARY INTAKE; DOWN SYNDROME; EARLY INTERVENTION; ENZYME ACTIVITY; EXERCISE; FAMILY HISTORY; FIRST DEGREE RELATIVE; FRACTURE; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENOTYPE; HUMAN; HYPERTENSION; INCIDENTAL FINDING; LONG TERM CARE; LONG TERM EXPOSURE; MEDICAL ETHICS; MILD COGNITIVE IMPAIRMENT; MUTATION; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OUTCOME VARIABLE; PATIENT COUNSELING; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PREVENTION STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM; THINKING; TREATMENT RESPONSE;

AD; ADNI; ALZHEIMER DISEASE; ALZHEIMER PREVENTION INITIATIVE; ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE; AMYLOID BETA; API; APOE; APOLIPOPROTEIN E; AΒ; BIOM+; BIOM-; BIOMARKER-NEGATIVE; BIOMARKER-POSITIVE; BIOMARKERS; CEREBROSPINAL FLUID; CSF; DIAN; DOMINANTLY INHERITED ALZHEIMER NETWORK; EARLY-ONSET FAMILIAL ALZHEIMER DISEASE; EOFAD; ETHICS; FDA; FOOD AND DRUG AGENCY; MAGNETIC RESONANCE IMAGING; MRI; PET; PIB-PET; POSITRON EMISSION TOMOGRAPHY; PREVENTION; REVEAL; RISK EVALUATION AND EDUCATION FOR ALZHEIMER'S DISEASE; TREATMENT; [(11)C]PITTSBURGH COMPOUND B POSITRON EMISSION TOMOGRAPHY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HEALTH INFORMATION MANAGEMENT; HUMANS; RISK FACTORS;

EID: 84886747917     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.12.001     Document Type: Review

References (60)

1. Aisen P.S. Alzheimer's disease therapeutic research: the path forward. Alzheimer's Research & Therapy 2009, 1:2.
2. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7:270-279.
3. Alzheimer's Disease International World Alzheimer Report 2010: Global Economic Impact of Dementia 2010, Alzheimer's Disease International, London, UK.
4. Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., Salloway S., Sperling R.A., Windisch M., Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's Research & Therapy 2011, 3:1.
5. Bateman R.J., Klunk W.E. Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics 2008, 5:381-390.
6. Beauchamp T.L., Childress J.F. Principles of Biomedical Ethics 2009, Oxford University Press, Oxford.
7. Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. Journal of Geriatric Psychiatry and Neurology 2010, 23:213-227.
8. Brief E., Illes J. Tangles of neurogenetics, neuroethics, and culture. Neuron 2010, 68:174-177.
9. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans 2010, December.
10. Cohen J. The cost of dichotomization. Applied Psychological Measurement 1983, 7:249-253.
11. Cox S.M., McKellin W. 'There's this thing in our family': predictive testing and the construction of risk for Huntington's Disease. Sociology of Health and Illness 1999, 21:622-646.
12. Cupples L.A., Farrer L.A., Sadovnick A.D., Relkin N., Whitehouse P., Green R.C. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genetics in Medicine 2004, 6:192-196.
13. DeKosky S.T., Fitzpatrick A., Ives D.G., Saxton J., Williamson J., Lopez O.L., Burke G., Fried L., Kuller L.H., Robbins J., Tracy R., Woolard N., Dunn L., Kronmal R., Nahin R., Furberg C. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemporary Clinical Trials 2006, 27:238-253.
14. Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology 2010, 9:1118-1127.
15. Eckert S.L., Katzen H., Roberts J.S., Barber M., Ravdin L.D., Relkin N.R., Whitehouse P.J., Green R.C. Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study. Genetics in Medicine 2006, 8:746-751.
16. Emanuel E.J., Wendler D., Grady C. What makes clinical research ethical?. Journal of the American Medical Association 2000, 283:2701-2711.
17. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., Wall A., Ringheim A., Langstrom B., Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
18. Erickson K.I., Voss M.W., Prakash R.S., Basak C., Szabo A., Chaddock L., Kim J.S., Heo S., Alves H., White S.M., Wojcicki T.R., Mailey E., Vieira V.J., Martin S.A., Pence B.D., Woods J.A., McAuley E., Kramer A.F. Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:3017-3022.
19. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nature Reviews Drug Discovery 2010, 9:749-751.
20. Feldman H.H., Jacova C. Primary prevention and delay of onset of AD/dementia. Canadian Journal of Neurological Sciences 2007, 34(Suppl. 1):S84-S89.
21. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
22. Goldman J.S., Hahn S.E., Catania J.W., Larusse-Eckert S., Butson M.B., Rumbaugh M., Strecker M.N., Roberts J.S., Burke W., Mayeux R., Bird T. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine 2011, 13:597-605.
23. Green R.C., Roberts J.S., Cupples L.A., Relkin N.R., Whitehouse P.J., Brown T., Eckert S.L., Butson M., Sadovnick A.D., Quaid K.A., Chen C., Cook-Deegan R., Farrer L.A. Disclosure of APOE genotype for risk of Alzheimer's disease. New England Journal of Medicine 2009, 361:245-254.
24. Horng S., Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB; A Review of Human Subjects Research 2003, 25:11-16.
25. Hsiung G.Y., Sadovnick A.D. Genetics and dementia: risk factors, diagnosis, and management. Alzheimer's & Dementia 2007, 3:418-427.
26. ICH Expert Working Group International Harmonized Tripartite Guideline: General Considerations for Clinical Trials: E8 1997, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Eff icacy/E8/Step4/E8_Guideline.pdf.
27. Illes J., Chin V. Trust and reciprocity: foundational principles for human subjects imaging research. Canadian Journal of Neurological Sciences 2007, 34:3-4.
28. Illes J., Kirschen M.P., Edwards E., Bandettini P., Cho M.K., Ford P.J., Glover G.H., Kulynych J., Macklin R., Michael D.B., Wolf S.M., Grabowski T., Seto B. Practical approaches to incidental findings in brain imaging research. Neurology 2008, 70:384-390.
29. Illes J., Kirschen M.P., Edwards E., Stanford L.R., Bandettini P., Cho M.K., Ford P.J., Glover G.H., Kulynych J., Macklin R., Michael D.B., Wolf S.M. Incidental findings in brain imaging research. Science 2006, 311:783-784.
30. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology 2010, 9:119-128.
31. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
32. Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., Hoyte K., Gustafson A., Liu Y., Lu Y., Bhangale T., Graham R.R., Huttenlocher J., Bjornsdottir G., Andreassen O.A., Jonsson E.G., Palotie A., Behrens T.W., Magnusson O.T., Kong A., Thorsteinsdottir U., Watts R.J., Stefansson K. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
33. Karlawish J.H.T. Making sense of the language of benefit for Alzheimer's disease treatments. Treating Dementia: Do We Have a Pill For It? 2009, 125-133. The Johns Hopkins University Press, Baltimore, MD. J.F. Ballenger, P.J. Whitehouse, C.G. Lyketsos, P.V. Rabins, J.H.T. Karlawish (Eds.).
34. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kareholt I., Winblad B., Helkala E.L., Tuomilehto J., Soininen H., Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Archives of Neurology 2005, 62:1556-1560.
35. Lautenschlager N.T., Cox K.L., Flicker L., Foster J.K., van Bockxmeer F.M., Xiao J., Greenop K.R., Almeida O.P. Effect of physical activity on cognitive function in older adults at risk for Alzheimer Disease. Journal of the American Medical Association 2008, 300:1027-1037.
36. Lock M., Hedgecoe A. APOE genotyping, risk estimates, and public understanding of susceptibility genes. Treating Dementia: Do We Have a Pill For It? 2009, 231-249. The Johns Hopkins University Press, Baltimore, MD. J.F. Ballenger, P.J. Whitehouse, C.G. Lyketsos, P.V. Rabins, J.H.T. Karlawish (Eds.).
37. Mattsson N., Andreasson U., Persson S., Arai H., Batish S.D., Bernardini S., Bocchio-Chiavetto L., Blankenstein M.A., Carrillo M.C., Chalbot S., Coart E., Chiasserini D., Cutler N., Dahlfors G., Duller S., Fagan A.M., Forlenza O., Frisoni G.B., Galasko D., Galimberti D., Hampel H., Handberg A., Heneka M.T., Herskovits A.Z., Herukka S.K., Holtzman D.M., Humpel C., Hyman B.T., Iqbal K., Jucker M., Kaeser S.A., Kaiser E., Kapaki E., Kidd D., Klivenyi P., Knudsen C.S., Kummer M.P., Lui J., Llado A., Lewczuk P., Li Q.X., Martins R., Masters C., McAuliffe J., Mercken M., Moghekar A., Molinuevo J.L., Montine T.J., Nowatzke W., O'Brien R., Otto M., Paraskevas G.P., Parnetti L., Petersen R.C., Prvulovic D., de Reus H.P., Rissman R.A., Scarpini E., Stefani A., Soininen H., Schroder J., Shaw L.M., Skinningsrud A., Skrogstad B., Spreer A., Talib L., Teunissen C., Trojanowski J.Q., Tumani H., Umek R.M., Van Broeck B., Vanderstichele H., Vecsei L., Verbeek M.M., Windisch M., Zhang J., Zetterberg H., Blennow K. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's & Dementia 2011, 7:386-395. e386.
38. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7:263-269.
39. Meinert C.L., McCaffrey L.D., Breitner J.C. Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results. Alzheimer's & Dementia 2009, 5:93-104.
40. Meiser B., Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. Journal of Neurology, Neurosurgery and Psychiatry 2000, 69:574-578.
41. MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results. British Medical Journal 1992, 304:405-412.
42. Nissen S.E., Wolski K., Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. Journal of the American Medical Association 2005, 294:2581-2586.
43. Opar A. Mixed results for disease-modification strategies for Alzheimer's disease. Nature Reviews Drug Discovery 2008, 7:717-718.
44. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
45. Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., Jack C.R., Jagust W.J., Shaw L.M., Toga A.W., Trojanowski J.Q., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010, 74:201-209.
46. Petersen R.C., Thomas R.G., Grundman M., Bennet D., Doody R., Ferris S., Galasko D., Jin S., Kaye J., Levey A., Pfeiffer E., Sano M., van Dyck C.H., Thal L.J. Vitamin E and donepzil for the treatment of mild cognitive impairment. New England Journal of Medicine 2005, 352:2379-2388.
47. Quigley H., Colloby S.J., O'Brien J.T. PET imaging of brain amyloid in dementia: a review. International Journal of Geriatric Psychiatry 2011, 26:991-999.
48. Reiman E.M., Langbaum J.B.S., Tariot P.N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers in Medicine 2010, 4:3-14.
49. Ringman J.M., Younkin S.G., Pratico D., Seltzer W., Cole G.M., Geschwind D.H., Rodriguez-Agudelo Y., Schaffer B., Fein J., Sokolow S., Rosario E.R., Gylys K.H., Varpetian A., Medina L.D., Cummings J.L. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008, 71:85-92.
50. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., Rodriguez Martinez de Liano S., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology 2010, 9:363-372.
51. 11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009, 73:1186-1192.
52. Shea B., Wells G., Cranney A., Zytaruk N., Robinson V., Griffith L., Ortiz Z., Peterson J., Adachi J., Tugwell P., Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Reviews 2002, 23:552-559.
53. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Journal of the American Medical Association 2003, 289:2651-2662.
54. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7:280-292.
55. Sperling R.A., Jack C.R., Aisen P.S. Testing the right target and right drug at the right stage. Science Translational Medicine 2011, 3:1-5.
56. Sperling R.A., Jack C.R., Black S.E., Frosch M.P., Greenberg S.M., Hyman B.T., Scheltens P., Carrillo M.C., Thies W., Bednar M.M., Black R.S., Brashear H.R., Grundman M., Siemers E.R., Feldman H.H., Schindler R.J. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer's & Dementia 2011, 7:367-385.
57. Steinbart E.J., Smith C.O., Poorkaj P., Bird T.D. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Archives of Neurology 2001, 58:1828-1831.
58. Tuokko H., Frerichs R.J. Cognitive impairment with no dementia (CIND): longitudinal studies, the findings, and the issues. Clinical Neuropsychology 2000, 14:504-525.
59. 11C]Pittsburgh compound B data. Annals of Neurology 2011, 70:857-861.
60. Wan H.I., Jacobsen S., Rutkowski J.L., Feuerstein G.Z. Translational medicine lessons from Flurizan's failure in Alzheimer's Disease (AD) trial: implication for future drug discovery and development for AD. Clinical and Translational Science 2009, 2:242-247.